21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj...

54
VJIL CONSULTING LIMITED 21 ST ANNUAL REPORT 2012 - 13 PDF processed with CutePDF evaluation edition www.CutePDF.com

Transcript of 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj...

Page 1: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

VJIL CONSULTING LIMITED

21ST

ANNUAL REPORT2012 - 13

PDF processed with CutePDF evaluation edition www.CutePDF.com

Page 2: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

1

Index Page

1. Notice 03

2. Director’s Report 05

3. Management Discussion & Analysis 09

4. Corporate Governance 12

5. Auditor’s Report 26

6. Balance Sheet 33

7. StatementofProfit&Loss 34

8. Cash Flow Statement 35

9 Notes 36

10. Attendance Slip/Proxy Slip 50

Page 3: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

2

BOARD OF DIRECTORS

Mr.M.Satyendra Chairman and Managing Director

Dr Garima Vashistha Director

Mr.J S S Murthy Director

Mr.G Nagendra Director

STATUTORY AUDITORS

M Anandam & Co.,Chartered Accountants7A, Surya Towers, S P RoadSecunderabad-500003

BANKERS

State Bank of HyderabadIndustrial Finance BranchPunjagutta, Hyderabad-82

REGISTERED OFFICE

3rd Floor Western Wing, NCC House,Survey No-64, Madhapur,Hyderabad-500 081.

REGISTRAR & SHARE TRANSFER AGENT

Bigshares Services Private LimitedFlat No. 306, Right Wing, 3rd floor,Amrutha Ville Apt., Opp.Yashodha Hospital,Raj Bhavan Road,Somajiguda, Hyderabad-500082

LISTED AT:

BSE Limited

Page 4: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

3

NOTICE

Notice is hereby given that the 21st Annual General Meeting of the members of the company will be held on Thursday 19th September, 2013 at 10.00 A.M. at Tyagaraya Gana Sabha, Chikkadpalli, Hyderabad - 500095 to transact the following business:

ORDINARY BUSINESS:

1) To receive, consider and adopt the Audited Balance Sheet of the company as at 31.03.2013 and theStatementofProfitandLossfortheyearendedonthatdateandtheReportoftheBoardofDirectors’ and the Auditor’s report thereon.

2) To appoint a director in place of Dr. Garima Vashistha who retires by rotation and being eligible, offers herself for re-appointment

3) To appoint retiring auditors who are eligible for the re-appointment as per Section 224 (1B) of the

Companies Act, 1956 from the conclusion of this Annual General Meeting till the conclusion of the next Annual General Meeting andfixingtheirremuneration.

By order of the Board Sd/- M.Satyendra Chairman & Managing Director

Place : HyderabadDate : 14.08.2013

Page 5: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

4

NOTES:

1. A member entitled to attend and vote at the meeting is entitled to appoint a proxy to attend and vote on a poll instead of him and such a proxy need not be a member of the company.

2. ProxiesinordertobeeffectivemustbereceivedattheCompany’sRegisteredOfficenotlessthan48 hours before commencement of the meeting.

3. The Register of the members and share transfer books of the Company will close from Monday, 16th September, 2013 to Thursday, 19th September, 2013 (Both days inclusive)

4. Members are requested to quote ledger folio numbers in all their correspondence to avoid delay in communication.

5. Members are advised to consolidate their ledger folios where they are holding shares in different folios in the same name/sequence of names.

ADDITIONAL INFORMATION ON DIRECTORS RETIRING BY ROTATION AND SEEKING RE-APPOINTMENT AT THE ENSUING ANNUAL GENERAL MEETING IN TERMS OF CLAUSE 49 OF THE LISTING AGREEMENT.

Dr.Garima Vashistha

Dr. Garima Vashistha is the president of life sciences at Tholons Inc. She serves life sciences clients in the areas of developing and implementing globalization strategies and managing operations. Dr. Garima has morethan20yearsofexperienceworkinginUSA,UK,CanadaandIndiainthefieldofLifeSciencesandIT.PriortofoundingTholons,sheco-foundedneoIT,aleadingoffshoreadvisoryfirm.Dr.Garimaworkedas a senior research scientist and lecturer in bio-chemistry, bio-physics, and bio-genesis department at the University of Colorado and University of Alberta. Her work experience includes drug development for Thio Pharmaceuticals and Bristol-Myers Pharmaceutical.

Shareholding in the Company: 340727 equity shares

She is member of Audit Committee, Remuneration committee and investor grievance committee of the Company and is neither a member nor chairman of any committee of any another company.

Page 6: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

5

DIRECTOR’S REPORTDear Members,

Your Directors are pleased to present the 21st Annual Report of your company together with the Audited BalanceSheetandStatementofProfitandLossofthecompanyforthefinancialyearended31.03.2013.

1. FINANCIAL RESULTS:

Financial results for the year under review and as well as previous year are as follows. ( InLakhs)

Particulars Year Ended Year Ended 31.3.2013 31.3.2012Income from Operations 310.03 143.46

PBDIT (148.10) (324.30)

Depreciation 31.97 39.37

Interest -- 90.98

ProfitBeforeTax(PBT) (180.07) (449.25)

Provision for Tax -- 4.32

ProfitAfterTax(PAT) (180.07) (453.57)

2. OPERATIONS:

Duringtheyearunderreview,yourCompanymadeaNetincomeofRs.310.03LakhsandincurredaNetLossofRs.180.07Lakhsafterprovidingfordepreciationandtax.TheoperationsoftheCompanywereaffected badly in the recent years due to differences in the management, which ultimately has resolved. Yourcompanyhasincurredlossesinthisfiscalduetoreductioninturnover,fixedoverheadsandotherexpenditure for getting new business.

3. DIVIDEND:

Due toabsencesofprofit, thedirectorsofyourCompanydonot recommendanydividend for thefinancialyear2012-13.

4. FIXED DEPOSITS:

Your Company has not accepted any deposits falling under Section 58A of the Companies Act, 1956 read with Companies (Acceptance of Deposits) Rules 1975 during the year.

Page 7: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

6

5. DIRECTORS:

Dr.Garima Vashistha, Director of the Company retires by rotation at the ensuing Annual General Meeting and being eligible offer herself for reappointment.

6. DIRECTORS RESPONSIBILITIES STATEMENT: In pursuance of Section 217(2AA) of the Companies Act, 1956 the Directors of your company hereby confirm:

(i) that in the preparation of Annual Accounts for the year ended 31st March, 2013, the applicable accounting standards have been followed along with the proper explanation relating to material departures;

(ii) that the directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the stateofaffairsofthecompanyattheendofthefinancialyearend,31stMarch,2013andoftheprofitandlossofthecompanyforthatperiod;

(iii) thatthedirectorshavetakenproperandsufficientcareforthemaintenanceofadequateaccountingrecords in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;

(iv) thatthedirectorshavepreparedtheannualaccountsonagoingconcernbasisforthefinancialyear 2012-13.

7. MANAGEMENT’S DISCUSSION ANALYSIS:

Management’s Discussion and Analysis report is enclosed to this report as Annexure – A

8. CORPORATE GOVERNANCE:

ReportonCorporateGovernancealongwithPracticingCompanysecretarycertificateonCompliancewiththecodeofCorporateGovernanceunderClause49oftheListingAgreementisenclosedasAnnexure – B to this report.

Page 8: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

7

9. AUDITORS:

M/s M. Anandam & Co., Chartered Accountants, retire at the conclusion of the ensuing Annual General Meetingandbeingeligibleforthere-appointment,offersthemselvesforreappointmentforthefinancialyear2013-14.YourCompanyhasreceivedacertificatefromthesaidAuditorstotheeffectthattheirre-appointment if made would be in accordance with the provisions of Section 224(1B) of the Companies Act, 1956.

10. AUDITORS’ OBSERVATIONS, QUALIFICATIONS AND EXPLANATIONS:

AuditorshavemadeQualifiedopinionintheAuditorsReportforwhichaproperexplanationhasgiveninNoteNo.29to32innotestofinancialstatement.

11. PARTICULARS OF EMPLOYEES:

None of the Employees of the Company is drawing remuneration exceeding limits prescribed under section 217(2A) of the Companies Act, 1956 read with the Companies (Particulars of Employees) Rules, 2011.

12. SUBSIDIARY:

As required under Section 212 of the Companies Act, 1956, the audited statements of accounts for the financialyearended31stMarch,2013alongwithreportoftheBoardofDirector’sandAuditoroftheCompany’sSubsidiary,M/sMercuryOutsourcingManagementLimitedcouldnotbefurnished.

13. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO:

a) Your company has taken adequate internal control procedures by which the cost of electricity shall beidentifiedwithprojectandthecompanywillprovideanincentivefortheconcerneddepartmentwhich consumes optimum power.

No additional investments for reduction of Energy consumption were taken up during the year under review.

b) Technology absorption: Not Applicable

Page 9: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

8

c. Foreign Exchange Earning and outgo( In lakhs)

Particulars 2012-13 2011-12Foreign Exchange Earnings 310.03 143.45Foreign Exchange Outgo 160.51 120.76 14. EMPLOYEE CONTRIBUTION:

The board wishes to place on record its sincere appreciation for their untiring efforts at all levels and various departments and showing good results in software development and training both in India and abroad.

15. ACKNOWLEDGEMENTS:

YourDirectorsalsoplaceonrecordtheirheartfeltgratitudeforthesupportextendedandconfidencereposed by the customers, shareholders, employees, Central and State Government agencies and suppliers and look forward for the same in future.

For and on behalf of the Board VJILCONSULTINGLIMITED

Sd/-

Place : Hyderabad M. Satyendra Date : 14.08.2013 Chairman and Managing Director

Page 10: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

9

MANAGEMENT DISCUSSION & ANALYSIS

Indian economy

“When the global economy is challenged, the Indian economy will also face challenges. It is the challenges that should bring out the best in the people. Finance Minister P.Chidambaram said that the Indianeconomyexpectstogrowbetween5.6to6percent inthecurrentfiscalonthebackofglobalchallenges and slowdown in investment. Just we consolidated that the Indian economy in 2012-2013 will take the economy one rung higher in 2013-2014. We are looking forward to a growth rate between 5.5 to 6 percent and we will take all measures to achieve goal” Chidambaram report.

The Indian economy is the fourth largest economy of the world on the basis of Purchasing Power Parity (PPP). It is one of the most attractive destinations for business and investment opportunities due to hugemanpowerbase,diversifiednaturalresourcesandstrongmacro-economicfundamentals.Also,theprocess of economic reforms initiated since 1991 has been providing an investor-friendly environment through a liberalized policy framework spanning the whole economy. In the budget, the Government had estimated the economic growth to be between 6.1 to 6.7 percent. The Asian Development Bank lowered its growth projection for India to 5.8 percent in calendar 2013 from 6 percent estimated earlier, citing the slow progress of economic reforms. Growth in Domestic Market:- The Indian IT Industry is growing steadily despite the global meltdown in the year 2009. When the whole of the world witnessed the negative growth, Indian IT industry still managed to register a growth of 5.5%. The industry is about to register the historic landmark of US $ 50 billion exports this year, according to NASSCOM president, Sona Mittal. The domestic market is slotted to witness 12% growth, this year. Potential size of Indian’s offshoring industry is estimated at US $ 120 to 180 billion by 2015. The industry currently employs around and provides indirect employment to around 2.5 million people.Itisexpectedtoaddanother1,50,000jobsinthenextfiscalaccordingtoNASSCOM.

Opportunities, Threats, Risks and Concerns:

India has been and remains the most favored offshore location for Technology Services. India is ranked at the top, ahead of China, Czech Republic and Philippines for offshore IT services.

USA is the biggest market for Indian Software and BPO Industry. However, due to economic slowdown, it has cut down expenditure on technology drastically. According to the PwC Global 100 Software Leadersreport,Indiaranksfifthamongtheemergingmarketsbasedonrevenues.TheIT/ITeSsectorhas led to employment opportunities, both direct and indirect, of nearly 2.8 million and around 8.9 million respectively. This growth is expected to increase to more than 14 million (direct and indirect) by 2015 and to around 30 million by 2030.

In the twelfth Five Year Plan (2012-17), the Department of Information Technology proposes to strengthen and extend the existing core infrastructure projects to provide more horizontal connectivity,

ANNEXURE- A

Page 11: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

10

build redundancy connectivity, undertake energy audits of State Data Centers (SDCs) etc. The core infrastructure including fibre optic based connectivity will be leveraged and additional 1,50,000Common Service Centres (CSCs) will be setup to create the right Governance and service delivery ecosystem at the Panchayat’s.

Risk management is an important aspect of our lives. We are exposed to risks, both in terms of threats to service provision and from the potential of lost opportunities. It is essential that of late, businesses should continue to demonstrate their unswerving commitment to consider implications arising out of the potential risks to meet client requirements and maintain their faith in the Operational Excellence of their teams and service providers. The International Monetary fund had projected slow growth in the advanced economies between 2012-2017.

VJIL focuses on IT core activities i.e., enterprise information management, enterprise integrationservices, Data Ware housing services. Its clients include organizations from various sectors of the economysuchasfinancial,healthcare,oil,andpharmaceuticals,retail,businessservices,education,ITand government.

Internal Controls and Their Adequacies

The Company has a proper and adequate internal control system commensurate with its size and nature of business to meet the following objectives:-

➢ Providingassuranceregardingtheeffectivenessandefficiencyofoperations;

➢ Efficientuseandsafeguardingofresources;

➢ Compliance with policies, procedures and applicable laws and regulations; and

These systems are IT enabled which facilitate effective checks and tight monitoring of all parameters and control on continuous basis

Human Resources / Industrial Relations

The Company believes and recognizes that its employees are a vital resource in its growth and to give competitive edge in the present business scenario.

The Company has a group of able and experienced employees. The Company believes that the quality of its employees is the key to its success in the long run. The Company continues to have cordial relations with its employees and provides personal development opportunities for all round exposure to them The Board of Directors wishes to place on record its appreciation for the hard work and dedication of its employees at all levels.

Page 12: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

11

Future Outlook

IT industry is one of the fastest growing industries among whole world. Indian IT industry has placed itself in the third position due to domestic as well as international market demand. Though ‘IT’, a smallwordbutitconvertstheentireworldintoaglobalvillage.TheintensificationofITstillliesinphenomenon and fantasy. From the last decade India has became one of the most important offshore destinationsamongsttheAsia-Pacificregion.During4to5yearsitincreasesupto3foldandcapturedthe leadership position in the world market. Indian IT sector acquires 3% of the total global market and it is expected to increase its volume in the next few years.

According to a study conducted by IT research firm Springboard Research, the vertical would beheavily dominated by infrastructure services, which are expected to reach $7.2 billion in 2013, while applications services, with a CAGR of 19.6 percent would be the fastest growing segment. In terms of industry verticals, Banking, Financial Services and Insurance (BFSI) leads the Indian IT services market with 21.5 percent market share, followed by the public sector (including education) and telecom industry. However, energy and utilities followed by healthcare remains the fastest growing vertical.

Despite2013ending inadifficulteconomicenvironment,somegeographicregionsandservicesareexpected to circumvent the situation in 2013. Global GDP, The World Bank estimates global GDP grew 2.3 percent in 2012 and is estimated the world economy would expand to grow 2.4 per cent in 2013. In 2014 the growth rate is expected to accelerate to 3 percent and reach 3.3 percent in 2015. With developing economies growing thrice as fast as the developed economies.

TheCompanyhasgoodprospectus in theComingsfinancial year andmanagement is confidentofgetting new projects.

For and on behalf of the Board

VJILCONSULTINGLIMITED

Sd/- Place : Hyderabad M. Satyendra Date : 14.08.2013 Chairman and Managing Director

Page 13: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

12

ANNEXURE –BCORPORATE GOVERNANCE REPORT

1. Brief statement On Company’s philosophy on code of governance.

VJILConsultingLimitedbelievesthatgoodcorporategovernanceisakeydriverofsustainablecorporategrowthandlong-termvaluecreationforitsshareholders.CorporateGovernanceatVJILConsultingLimiteddoesnotonlymeanensuring thecompliancewith regulatory requirements,butalsobeingresponsivetoaspirantsofcustomers/clientsandexpectationsofthesociety.VJILConsultingLimitedalways strives for excellence in quality of goods and services with the twin objectives of enhancing customer satisfaction and shareholder value.

We are committed to upgrade our systems, processes and disclosure norms to achieve high standards of Corporate Governance.

2. BOARD OF DIRECTORS:

• Composition of the Board:

At present, the strength of the Board is Four Directors. The Board comprises of 1 Executive and 1 Non-Executive Director and 2 Non Executive & Independent Directors.

S. No Director Category Attendance Attendance in Other Boards at AGM held Board Meeting on 28.09.2012 Held Attend- Director Committee Committee ance ship Chairman member ship ship

1 Mr. M. Satyendra Chairman and Managing Director YES 5 5 1 Nil Nil

2 Dr. Garima Vashistha Non-Executive YES 5 4 3 Nil Nil Director

3 Mr. G.Nagendra Non-Executive & YES 5 5 Nil Nil Nil Independent Director

4 Mr. J S S Murty Non-Executive & YES 5 3 Nil Nil Nil Independent Director

Page 14: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

13

•Board meeting and attendance

Five Board Meetings were held during the Financial Year and the gap between two board meetings did not exceed four months.

The dates on which meeting were held are as follows:

14-05-2012 13-08-2012 27-08-2012 14-11-2012 11-02-2013

3. AUDIT COMMITTEE:

a) Brief description of terms of reference

• Reviewtheun-auditedquarterlyresults,halfyearlyandannualaccountsofthecompany.

• Oversee the Company’s financial reporting process and the disclosure of its financialinformationtoensurethatthefinancialstatementiscorrect,sufficientandcredible.

• Recommendingtheappointmentandremovalofstatutoryauditors,fixationofauditfeeandalso approval for payment of any other services.

• Reviewingwith themanagement, theannualfinancialstatementsbeforesubmission to theBoard focusing primarily on:

(i) Any changes in accounting policies and practices (ii) Major accounting entries based on exercise of judgment by management (iii) Qualificationsindraftauditreports (iv) Significantadjustmentsarisingoutoftheaudit (v) The going concern assumption (vi) Compliance with accounting standards

• Any related party transactions i.e. transactions of the company of material nature, withpromoters or the management, their subsidiaries or relative etc.; that may have potential conflictwiththeinterestsofthecompanyatlarge.

• Reviewingwithmanagement,externalandinternalauditors,theadequacyofinternalcontrolsystems.

• Reviewingtheadequacyofinternalauditfunction,includingthestructureoftheinternalauditdepartment,staffingandseniorityoftheofficialheadingthedepartment,reportingstructurecoverage and frequency of internal audit.

• Discussionwithinternalauditorsanysignificantfindingsandfollow-upthereon.

• Reviewing thefindingsof any internal investigationsby the internal auditors intomatterswhere there is suspected of fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the board.

Page 15: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

14

• Discussionwithexternalauditorsbefore theauditcommences,on thenatureandscopeofaudit as well as has post- audit discussion to ascertain any areas of concern.

• Reviewingthecompany’sfinancialandriskmanagementpolicies.

• To look into and review the reasons for substantial defaults, if any, in payments to thedepositors, debenture holders, shareholders (in case of non-payment of declared dividends) and creditors;

b) COMPOSITION OF AUDIT COMMITTEE

The Audit Committee of the Company consists of the Following members:

Name of the Director Designation

Mr G. Nagendra Chairman

Mr. J S S Murthy Member

Dr. Garima Vashistha Member

The committeemet 5 timesduring thefinancial year 2012-13 on, 14.05.2012, 13.08.2012, 27.08.2012,14.11.2012 and 11.02.2013 attendance of each Member of Committee is as follows.

S. No. Name of the Member Designation No of Meetings No of Meetings held during the Year attended

1 Mr. G.Nagendra Chairman 5 5

2 Dr. Garima Vashistha Member 5 4

3 Mr. J S S Murthy Member 5 3

The role of the audit committee includes recommending the appointment and removal of the external auditor,discussionoftheaudit,plan,andfixationofauditfeeandalsoapprovalofpaymentoffeesforany other services.

4. REMUNERATION COMMITTEE

The terms of reference of the Remuneration Committee are as follows:

• TheRemunerationCommitteerecommendstotheboardthecompensationtermsoftheexecutive directors / non-executive directors.

• FramingandimplementingonbehalfoftheBoardandonbehalfoftheshareholders,acredible and transparent policy on remuneration of executive directors including ESOP, Pension Rights and any compensation payment.

• ConsideringapprovingandrecommendingtotheBoardthechangesindesignationandincrease in salary of the executive directors.

Page 16: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

15

• Ensuringtheremunerationpolicyisgoodenoughtoattract,retainandmotivatedirectors.

• Bringingaboutobjectivityindeemingtheremunerationpackagewhilestrikingabalancebetween the interest of our Company and the shareholders.

• Composition

The Remuneration Committee of the following members

S.No. Name of the Member Designation

1 Mr G. Nagendra Chairman

2 Mr. J S S Murthy Member

3 Dr. Garima Vashistha Member

Thecommitteemet1timeduringthefinancialyear2012-13on14.05.2012attendanceofeachMemberof Committee is as follows.

S. No. Name of the Member Designation No of Meetings No of Meetings held during the Year attended

1 Mr. G.Nagendra Chairman 1 1

2 Dr. Garima Vashistha Member 1 1

3 Mr. J S S Murthy Member 1 1

F Remuneration paid to Directors during the Financial Year

Details of Remuneration paid to the Executive Directors during the year 2012-13 are as under:

Name of the Director Designation Remuneration (In )

M. Satyendra Chairman & Managing Director 24,00,000

No sitting fees is paid to the other directors of the Company

5. INVESTOR GRIEVANCE COMMITTEE

• Terms of Reference:

The terms of reference of the Investor Grievance & Share Transfer Committee are as follows:

Page 17: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

16

To supervise and ensure:

(i) Efficienttransferofshares;includingreviewofcasesforrefusaloftransfer/transmissionofshares and debentures;

(ii) Redressal of shareholder and investor complaints like transfer of shares, non-receipt of balance sheet, non-receipt of declared dividends etc;

(iii) Issueofduplicate/split/consolidatedsharecertificates;

(iv) Allotment and listing of shares;

(v) Review of cases for refusal of transfer / transmission of shares and debentures;

(vi) Reference to statutory and regulatory authorities regarding investor grievances;

(vii) And to otherwise ensure proper and timely attendance and redressal of investor queries and grievances.

F Composition

The Committee of the following members

S.No. Name of the Member Designation

1 Sri. G. Nagendra Chairman

2 Sri. M Satyendra Member

3 Dr. Garima Vashistha Member

Thecommitteemet4timesduringthefinancialyear2012-13on14.05.2012,13.08.2012,14.11.2012and11.02.2013 attendance of each Member of Committee is as follows.

S. No. Name of the Member Designation No of Meetings No of Meetings held during the Year attended

1 Mr. G.Nagendra Chairman 4 4

2 M Satyendra Member 4 4

3 Dr. Garima Vashistha Member 4 2

Name&DesignationoftheComplianceOfficer : Mr.M.Satyendra Chairman & Managing Director

Page 18: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

17

No. of shareholders complaints received during the Financial Year : 2No. of complaints solved to the satisfaction of the share holders : 0No. of pending complaints : 2

6. GENERAL BODY MEETINGS:a) The last three Annual General Meetings of the Company were held as under.

Financial Year Date Venue Time

2011-2012 28.09.2012 Hotel Swagath Conference Hall, Ameerpet ‘X’ Road, Opposite 10.00 A.M. Chowdary Mansion, Hyderabad - 16.

2010-2011 30.09.2011 Tyagaraya Gana Sabha, Chikkadapally, Hyderabad 10.00 A.M.

2009-2010 12.01.2011 Tyagaraya Gana Sabha, Chikkadapally, Hyderabad 12.00 P.M.

b) Whether any Special Resolutions passed in the previous 3 Annual General Meetings: - YES

In the AGM held on 30th September, 2011 members vide special resolution Appointed Sri M Satyendra as Chairman & Managing Director for a period of 3 years

POSTAL BALLOT:

NOspecialresolutionispassedunderPostalballotduringthefinancialyearunderreview.

No Special Resolution is proposed to be conducted through postal ballot at the ensuing Annual General Meeting.

7. DISCLOSURES

a) DisclosuresonmateriallysignificantrelatedpartytransactionsthatmayhavepotentialconflictwiththeinterestsofCompanyatlarge-NIL

b) Details of non-compliance by the Company, penalties, and structures imposed on the Company by Stock Exchange or SEBI or any statutory authority, on any matter related to capital markets, duringthelastthreeyears-NIL

8. MEANS OF COMMUNICATION.

Quarterly Results and Annual Results of the Company are normally published in Financial Chronicle and Andhra Bhoomi

Page 19: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

18

AsrequiredbyClause49oftheListingAgreement,ManagementDiscussionandAnalysisreportisapart of the Annual Report.

Web Site: www.vjil.com

9. GENERAL SHAREHOLDER INFORMATION

a) Annual General Meeting:

Date : 19th September, 2013

Time : 10.00 a.m.

Venue : Tyagaraya Gana Sabha, Chikkadpalli, Hyderabad - 500095

b) Financial Year : 1st April to 31st March

CALENDER OF EVENTS:

Event Dates

First Quarter un-audited Financial Results Second Week of August, 2013

Second Quarter un-audited Financial Results Second Week of November, 2013

Third Quarter un-audited Financial Results Second Week of February, 2014

FourthQuarterAuditedFinancialResults LastWeekofMay,2014

c) DATES OF BOOK CLOSURE

Monday, 16th September, 2013 to Thursday, 19th September, 2013 (Both days Inclusive)

d) Dividend Date: Within 30 days from the date of declaration at Annual General Meeting.

e) LISTING ON STOCK EXCHANGES

Name of the Stock Exchange Address Scrip Code

BSELimited PhirozeJeejeebhoyTowers, 517429 Dalal Street, MUMBAI – 400001

Page 20: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

19

f) STOCK DATA

MonthlyHighandLowpricesofVJILConsultingLimitedattheStockExchange,Mumbai(BSE)and performance in comparison to broad-based indices for the year ended 31st March, 2013 are furnished hereunder.

Month BSE LIMITED SHARE PRICE (Rs.)

HIGH LOW

April, 2012 15.00 13.05

May, 2012 14.20 12.10

June, 2012 15.29 11.94

July, 2012 15.64 14.00

August, 2012 15.64 12.91

September, 2012 14.43 11.41

October, 2012 13.66 11.30

November, 2012 13.65 11.76

December, 2012 13.49 11.51

January, 2013 13.40 10.19

February, 2013 12.20 8.55

March, 2013 9.87 5.34

g) REGISTRAR & TRANSFER AGENTS

BigsharesServicesPrivateLimited FlatNo.306,RightWing,3rdfloor, Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 Telephone No. 040-23374967 Fax No : 040-23370295 E-mail : [email protected]

Page 21: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

20

h) SHARE TRANSFER SYSTEM:

All the physical share transfers received are processed by the Share Transfer Agents M/s. BigsharesServicesPrivateLimited,Hyderabad.TheCompanyhasenteredintoagreementwithbothNSDL andCDSL to dematerialize its shares,which enable theCompany’s shares to betransferred electronically through Depositories System

• DEMAT ISIN NUMBER

Under the Depository System the International SecuritiesIdentificationNumber(ISIN)allottedtothe INE576B01019 Company’sEquitySharesbyNSDL&CDSL

i) Distribution of shareholding as on 31st March, 2013

Shares or debenture No. of holders % Shares / Debe- % holding of nominal ntures Amount value of Rs.

1 - 5000 6387 89.96 11469940 14.595001 - 10000 353 4.97 2959540 3.7710001 - 20000 161 2.27 2416310 3.0720001 - 30000 45 0.63 1144670 1.4630001 - 40000 23 0.33 820690 1.0440001 - 50000 27 0.38 1238900 1.5850001 - 100000 32 0.45 2427920 3.09100001 - above 72 1.01 56108030 71.40

TOTAL 7100 100.00 78586000 100.00

Page 22: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

21

j) Shareholding Pattern as on 31st March, 2013

Sl no Category No. of Shares Held % of Shareholding

A 1 INDIAN PROMOTERS & PROMOTER GROUP Individuals/Hindu Undivided Family 1880943 23.93 Central Government /State Governments Bodies Corporate Financial Institutions/Banks

Sub Total of A1 1880943 23.93

A 2 FOREIGN

Individuals (Non-Residents) Individuals (Foreign Individuals) Bodies Corporate Institutions Any Other (Specify) Sub Total of A2 - -

TOTAL OF A1 +A2 1880943 23.93

B 1. Public Shareholdings Institutions Mutual Funds and UTI Banks/Financial Institutions 100 - Central Government/State Government Venture Capital Funds Insurance Companies Foreign Institution Investor Foreign Venture Capital Investors Any Other (Specify)

Sub Total B1 100 -

B 2 Non Institutions

Bodies Corporate 504807 6.42 Individuals Individuals share holders holdings 2114838 26.91 nominalsharecapitaluptoRs.1Lakhs

Individual Shareholding holding 2456136 31.25 nominalsharecapitalinexcessofRs.1Lakhs

Page 23: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

22

Any Other (Specify)

NRIs/OCBs 873706 11.12 Foreign Collaborators Clearing Members 28070 0.36 Sub Total B2 5977557 76.07

TOTAL OF PUBLIC SHAREHOLDING (B1+B2) 5977657 76.07

C Shares held by Custodian and against which Depository Receipts have been issue Nil -

TOTAL A+B+C 7858600 100

The Company’s shares are available for dematerialization on both the Depositories i.e., National SecuritiesDepositoryLimited(NSDL)andCentralDepositoryServices(India)Limited(CDSL).88.64%of shares have been dematerialized as on 31.03.2013.

k) DEMATERIALIZATION OF SHARES AND LIQUIDITY: Since the Company has already entered intoagreementwithboththedepositories,viz.,NSDLandCDSLfordematerializationof itsshares,the shareholders are free to dematerialize their shares and keep them in dematerialized form with any Depository Participant.

l) Outstanding GDRs/ADRs/Warrants or any Convertible instruments, conversion date and likely impact on equity: Not Issued

m) Address for correspondence:

VJIL CONSULTING LIMITED 3rd Floor Western Wing, NCC House, Survey No-64, Madhapur, Hyderabad-500081 Telephone No. 040-23119633, 040-23119634 Fax No : 040-23119614 E-mail : [email protected]

CEO & CFO CERTIFICATION:

TheChairman&ManagingDirectoroftheCompanygaveannualcertificatesonfinancialreportingandinternal controls to the Boards in terms of Clause 49 copy enclosed as annexure to this report.

Page 24: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

23

DECLARATION OF MANAGING DIRECTOR ON COMPLIANCE WITH CODE OF CONDUCT AND ETHICS

VJILCONSULTINGLIMITEDhasadoptedCodeofBusinessConductandEthics(“thecode”)whichappliedto all the employees and Director of the Company. Under the Code, it is responsibility of all employees and Directors to familiarize themselves with the Code and comply with its Standards.

I, M satyendra, Chairman & Managing Director of the Company hereby certify that the Board members and seniormanagementpersonnelofVJILCONSULTINGLIMITEDhaveaffirmedcompliancewiththeCodeofconduct for the Financial Year 2012-13.

Sd/-

Place : Hyderabad M. Satyendra Date : 14.08.2013 Chairman and Managing Director

Page 25: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

24

REPORT ON CORPORATE GOVERNANCE(UnderClause49oftheListingAgreement)

ToTheMembersofVJILConsultingLimited

We have examined the compliance of the conditions ofCorporateGovernance byVJILConsultingLimited (theCompany) for theyear endedMarch31, 2013as stipulated in clause49of theListingAgreements of the said Company with Stock Exchanges in India.

The Compliance of conditions of Corporate Governance is the responsibility of the management. Our examination was limited to procedure and implementation thereof, adopted by the Company for insuring the compliance of the conditions of Corporate Governance. It is neither an audit nor an expressionofopiniononthefinancialstatementsoftheCompany.Inouropinionandtothebestofourinformation and according to the explanations given to us, we certify that the Company has complied withtheconditionsofCorporateGovernanceasstipulatedintheabove-mentionedListingAgreement.

We state that in respect of investor grievances received during the year ended 31st March, 2013 no investor grievances are pending for a period exceeding one month against the Company as per the records maintained by Company. We further state that such compliance is neither an assurance as to thefutureviabilityoftheCompanynortheefficiencyoreffectivenesswithwhichthemanagementhasconducted the affairs of the Company.

For P S Rao & Associates Company Secretaries

Sd/- N Vanitha Company secretary CP No. 10573 Place: Hyderabad Date: 14.08.2013

Page 26: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

25

Chief Executive Officer and Chief Finance Officer (CEO&CFO) Certificate:

I,M.Satyendra,Chairman&ManagingDirectorofVJILConsultingLimited,tothebestofourknowledgeand belief, certify that:

1. IhavereviewedtheBalanceSheetandProfitandLossAccountandallitsschedulesandnotesonaccounts as well as the Cash Flow Statement for the year ended 31.03.2013.

2. To the best of our knowledge and belief:

a. These statements do not contain any untrue statement or omit any material fact or contain statements that might be misleading.

b. Thefinancialstatementsandotherfinancial informationincludedinthisreportpresenttrue and fair view of the Company’s affairs and are in compliance with existing accounting standards and applicable laws and regulations.

3. To the best of our knowledge and belief, there are no transactions entered into by the Company during the year which are fraudulent, illegal or volatile of the Company’s code of conduct.

4. Weacceptresponsibilityforestablishingandmaintaininginternalcontrolsforfinancialreporting.We have evaluated the effectiveness of internal control systems of the Company pertaining to financialreportingandhavedisclosedtotheAuditorsandtheAuditCommittee,deficienciesinthe design or operation of such internal controls, if any, of which we are aware and steps taken or proposedtobetakenforrectifyingthesedeficiencies.

5. a) There has not been any significant change in internal control over financial reporting

during the year under reference;

b) Therehasnotbeenanysignificantchangesinaccountingpoliciesduringtheyearunderreference; and

c) Wearenotawareofanyinstancesduringtheyearofsignificantfraud,withinvolvementthereinofthemanagementoranyemployeehavingasignificantroleintheCompany’sinternalcontrolsystemoverfinancialreporting.

Place: Hyderabad Sd/-Date: 14.08.2013 M. Satyendra Chairman & Managing Director

Page 27: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

26

AUDITOR’S REPORTToThe Members of VJILConsultingLimitedHyderabad

Report on the Financial Statements

WehaveauditedtheaccompanyingfinancialstatementsofVJILConsultingLimited(“theCompany”),whichcomprisetheBalanceSheetasat31stMarch,2013,theStatementofProfitandLossandCashFlowStatementfortheyearthenended,andasummaryofsignificantaccountingpoliciesandotherexplanatory information.

Management’s Responsibility for the Financial Statements

Management is responsible forthepreparationofthesefinancialstatementsthatgiveatrueandfairviewof thefinancialposition,financialperformanceandcashflowsof theCompany inaccordancewith the Accounting Standards referred to in sub-section (3C) of section 211 of the Companies Act, 1956 (“the Act”). This responsibility includes the design, implementation and maintenance of internal control relevanttothepreparationandpresentationofthefinancialstatementsthatgiveatrueandfairviewand are free from material misstatement, whether due to fraud or error.

Auditor’s Responsibility

Our responsibility is to express anopinionon thesefinancial statements basedonour audit.Weconducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and performtheaudittoobtainreasonableassuranceaboutwhetherthefinancialstatementsarefreefrommaterial misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures inthefinancialstatements.Theproceduresselecteddependontheauditor’sjudgment,includingtheassessmentoftherisksofmaterialmisstatementofthefinancialstatements,whetherduetofraudorerror. In making those risk assessments, the auditor considers internal control relevant to the Company’s preparationandfairpresentationofthefinancialstatementsinordertodesignauditproceduresthatareappropriate in the circumstances. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by management, as well as evaluatingtheoverallpresentationofthefinancialstatements.

Webelievethattheauditevidencewehaveobtainedissufficientandappropriatetoprovideabasisforour audit opinion.

Basis for Qualified Opinion

1. Absenceoffixedassets register for earlieryears andnonascertainmentofdiscrepanciesonphysical verificationoffixedassetsascomparedtobookrecords.Theimpactontheaccountsisnotascertained(NoteNo.30ofthefinancialstatements)

Page 28: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

27

2. AsstatedinNoteno.31tothefinancialstatementsduetononconfirmationandnonreconciliationcertain long term trade receivables of Rs.176.29 lakhs , deposits of Rs.19.00 lakhs, loans and advances of Rs.234.46 lakhs, long term borrowings of Rs.216.29 lakhs and other current liabilities of Rs.62.46 lakhs as at March 31, 2013, relating to old outstandings, we are unable to comment on the balances of the accounts referred above as at the year-end and the consequential effect due to nonconfirmationandnonreconciliation,ifany,fortheyearisnotascertainable.

3. Non-provisioning for investments of Rs.292.10 lakhs and loans and advances of Rs.276.09 lakhs and long term trade receivables of Rs. 45.00 lakhs relating to subsidiary and Rs.306.30 lakhs included in long term trade receivables and other advances the impact on the accounts is not ascertained. (NoteNo.31and32tothefinancialstatements)

4. The Company has not provided interest in respect of outstanding long term borrowings of Rs 216.29 lakhsasatMarch31,2013.AsstatedinNoteNo.20tothefinancialstatementsthemanagementis in the discussion with the parties of the unsecured loans for reduction/waiver of interest in respect of the above referred amount. The impact on the accounts is not ascertained.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, except for theeffectsofthematterdescribedintheBasisforQualifiedOpinionparagraph,thefinancialstatementsgive the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India:

a) in the case of the Balance Sheet, of the state of affairs of the Company as at 31st March, 2013;

b) inthecaseoftheStatementofProfitandLoss,oftheprofitfortheyearendedonthatdate;and

c) inthecaseoftheCashFlowStatement,ofthecashflowsfortheyearendedonthatdate.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor’s Report) Order, 2003 (“the Order”) issued by the Central Government of India in terms of sub-section (4A) of section 227 of the Act, we give intheAnnexureastatementonthemattersspecifiedinparagraphs4and5oftheOrder.

2. As required by section 227(3) of the Act, we report that:

a) We have obtained all the information and explanations which to the best of our knowledge and belief werenecessary for the purpose of our audit;

b) In our opinion proper books of account as required by law have been kept by the Company so far as appears from our examination of those books;

Page 29: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

28

c) TheBalanceSheet,StatementofProfitandLoss,andCashFlowStatementdealtwithby this Report are inagreement with the books of account;

d) Inouropinion, theBalanceSheet, StatementofProfit andLoss, andCashFlowStatement comply with theAccounting Standards referred to in sub-section (3C) of section 211 of the Companies Act, 1956;

e) On the basis of written representations received from the directors as on March 31, 2013, and taken on record by the Board of Directors, none of the directors is disqualifiedason31stMarch,2013,frombeingappointedasadirectorintermsofclause (g) of sub-section (1) of section 274 of the Companies Act, 1956.

For M.Anandam & Co., Chartered Accountants (Firm Regn No. 000125S)

Sd/- S.Venkateswarlu PartnerPlace : Secunderabad M.No: 022790Date : 30th May, 2013

Page 30: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

29

Annexure Re: VJIL Consulting Limited

Referred to in Paragraph 1 under the heading of “Report on Other Legal and Regulatory Requirements” of our report of even date

i. a. The Fixed assets register of the Company for earlier years is not traceable and the ManagementisintheprocessofupdationoftheFixedAssetsregister.Thevalueoffixedassets is subject to review by the Management and reconciliation. The consequential impact on the accounts is not ascertainable at present.

b. The records of the Fixed Assets of the Company for earlier years were not available for our verificationforwhichwewereinformedthatthesamewerenottraceableandeffortsarebeingmadetolocatethem.Managementduringtheperiodhasphysicallyverifiedsomepart of the Assets. In the absence of the records we are not in a position to state whether there were any serious discrepancies between the records and physical assets.

c. In our opinion, and according to the information and explanations given to us, the Companyhasnotdisposedofanysubstantialpartofitsfixedassetssoastoaffectitsgoingconcern status.

ii. a. The inventory consists of computer software and course material only. The computer

software represents the development expenditure incurred by the company and capitalized over the years. As per the Management, this being a software product, the inventory is not physicallyverifiable.TheManagementhasphysicallyverifiedthecoursematerialduringthe year.

b. Theproceduresofphysicalverificationofcoursematerialfollowedbythemanagementisadequate in relation to the volume and value of the course material.

c. The Company has furnished records of its course material and as per the management no material discrepancies were observed.

iii. a. According to the information and explanation given to us, the Company has granted loan to one company covered in the register maintained under section 301 of the Companies Act, 1956. The maximum amount involved during the year was Rs. 48.45 lakhs and the year-end balance of loans taken from such parties was Rs. 48.45 lakhs .

b. As per the information and explanations given to us, the loan given to companies are

interest bearing and no repayment terms are stipulated. Based on the above, the rate of interest on which loans have been given to parties listed in the register maintained under section 301 of the Companies Act, 1956 are not prima facie prejudicial to the interest of the company.

c. There has been no receipt during the year either towards principal or interest. We have not made any comments because the terms of repayment have not been stipulated.

d. In cases where the overdue amount is more than rupees one lakh, Management has informed that reminders have not been sent to the parties for recovery of interest and principal.

Page 31: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

30

e. Asperinformationprovided,theCompanyhastakenloansfromfivepartiescoveredinthe register maintained under section 301 of the Companies Act, 1956. The maximum amount involved during the year was Rs. 63.50 lakhs and the year-end balance of loans taken from such parties was Rs. 63.50 lakhs.

f. As per the information and explanations given to us, these loans are interest bearing and no repayment terms are stipulated. Based on the above, the rate of interest and other terms and conditions on which loans have been taken from parties listed in the register maintained under section 301 of the Companies Act, 1956 are not prima facie prejudicial to the interest of the company.

g. There has been no payment during the year either towards principal or interest. We have not made any comments because the terms of repayment have not been stipulated.

iv. In our opinion and in accordance to the information and explanation given to us the company have adequate internal control system commensurate with the size of the company and the natureofitsbusiness,forthepurchaseofinventoryandfixedassetsandforthesaleofgoodsand services.

v. During the year the Company has not made any transactions with respect of parties covered in the register maintained u/s 301 of the Companies Act, 1956.

vi. The Company has not accepted any deposits from the public.

vii. In our opinion, the internal audit system of the company is strengthened so as to be commensurate with the size and nature of the business.

viii. The central government has not prescribed the maintenance of cost records under Clause (d) of sub section (1) of Section 209 of the Companies Act, 1956 in respect of services carried out by the company.

ix. a. According to the information and explanation given to us and on the basis of our examination of books of accounts, the company is not regular in depositing the undisputed statutory dues of providentfund,servicetax,taxdeductedatsource,professionaltaxandfringebenefittaxwiththe appropriate authorities. Arrears of undisputed amount outstanding as at 31st March, 2013 for a period of more than six months from the date they became payable are as follows:

Statutory Dues Amount outstanding as on 31st March, 2013 (in ` )

Tax Deducted At Source 52,45,545 Service Tax 3,24,991 Professional Tax 9,28,264 Provident Fund 40,62,176 FringebenefitTax 13,45,137

Page 32: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

31

b. The statement of disputed dues as required by the clause are as given under:

Name of the Statute Nature of Amount Financial year Forum where the Dues to which the disputes are amount relates pending

The Income Tax Act, 1961 Income tax 60,41,474 2004-05 High Court of AP

Income Tax Act, 1961 TDS 2,82,25,409 2007-08 CIT(Appeals)

Income Tax Act, 1961 TDS 2,17,98,425 2008-09 CIT(Appeals)

x. The company has accumulated losses of Rs.12,04,67,105 as at 31st March, 2013 and the company hasincurredcashlossesofRs.1,48,10,381/-duringthecurrentfinancialyear.

xi. In our opinion and according to the information and explanations given to us, the Company has notdefaultedinrepaymentofduestoanyfinancialinstitutionsorbank.Thecompanyhasnotissued any debentures.

xii. The company has not granted loans and advances on the basis of security, pledge of shares, debentures and other securities.

xiii. The Company is not a chit fund or a nidhi/mutual benefit fund/society. Accordingly theprovisions of clause 4(xiii) of the Companies (Auditors’ Report) Order, 2003 are not applicable to the Company.

xiv. In our opinion and according to the information and explanation given to us, the Company is not dealing in shares, securities, debentures and other investments. Accordingly, the provisions of clause 4(xiv) of the Companies (Auditors’ Report) Order, 2003 are not applicable to the Company.

xv. In our opinion and according to the information and explanations given to us, the Company has notgivenanyguaranteeforloantakenbyothersfrombanksorfinancialinstitutions.Accordingly,the provisions of clause 4(xv) of the Companies (Auditors’ Report) Order, 2003 are not applicable to the Company.

xvi. In our opinion and according to the information and explanation given to us, the term loans have been applied for the purpose for which they were raised.

xvii. In our opinion and according to the information and explanation to us, and on an overall examination of the Balance sheet of the Company, we report that no funds raised on short-term basis have been used for long term investments.

Page 33: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

32

xviii. The Company has not made any preferential allotment of shares during the year

xix. The Company has not issued any debentures during the year. Accordingly the provisions of clause 4(xix) if the Companies (Auditors’ Report) Order, 2003 are not applicable to the Company.

xx. The Company has not raised any funds on public issue and hence disclosure on the end use of money raised by the public issue is not applicable to the Company.

xxi. To the best of our knowledge and belief and according to the information and explanations given to us, no fraud on or by the company was noticed or reported during the year.

For M.Anandam & Co., Chartered Accountants (Regn No. 000125S)

Sd/- S.Venkateswarlu PartnerPlace : Secunderabad M.No: 022790Date : 30th May, 2013

Page 34: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

33

I. EQUITY AND LIABILITIES (1) Shareholders’ Funds (a) Share Capital 2 78,586,000 78,586,000 (b) Reserves and Surplus 3 (62,506,295) (40,785,969) (2) Non-Current Liabilities (a)Long-termborrowings 4 21,629,687 20,875,037 (b) Deferred tax liabilities (Net) 5 104,650 104,650 (c)OtherLongtermLiabilities 6 118,700,000 99,700,000(d)Longtermprovisions 7 1,320,551 949,918 (3) Current Liabilities (c) Other current liabilities 8 69,217,013 67,150,604 (d) Short-term provisions 9 3,069,024 3,139,657

Total 230,120,631 229,719,897 II. ASSETS (1) Non-current assets (a) Fixed assets (i) Tangible assets 10 39,448,416 40,515,809 (ii) Capital work-in-progress 5,552,963 5,552,963 (b) Non-current investments 11 29,210,600 29,210,600 (c)Longtermloansandadvances 12 64,279,732 62,173,887(d) Other Non Current Assets 13 22,129,163 22,647,860

(2) Current assets (a) Inventories 14 58,588,252 58,588,252 (b)Trade receivables 15 8,590,727 6,944,905 (c) Cash and cash equivalents 16 2,320,777 4,085,621 Total 230,120,631 229,719,897 SignificantAccountingPolicies 1

Particulars Note No. 31st March, 2013 31st March, 2012

BALANCE SHEET AS AT 31ST MARCH, 2013

For and on behalf of the Board

Sd/- Sd/- M.SATYENDRA G.NAGENDRA Chairman & Managing Director Director

As per our report of even date attachedFor M. Anandam & Co.,Chartered Accountants Sd/-S.VENKATESWARLU PartnerM.No.022790

Place : HyderabadDate : 30-05-2013

(Amount in )

Page 35: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

34

INCOMEI. Revenue from operations 17 31,002,715 14,345,519 II. Other Income 18 197,832 19,252 Total Revenue (I +II) 31,200,547 14,364,771 EXPENDITURE Employeebenefitsexpense 19 21,126,111 17,660,229Finance Costs 20 - 9,097,708 Depreciation 10 3,197,022 3,937,643 Other Expenses 21 24,884,817 28,594,930 Total Expenses 49,207,950 59,290,510 Profitbeforetax (18,007,403) (44,925,739)Tax expense: Current tax - - Tax for the earlier years 431,732 Deferred tax - - ProfitAfterTax (18,007,403) (45,357,471)Earnings per equity share: 26 (1) Basic (2.29) (5.72) (2) Diluted (2.29) (5.72)SignificantAccountingPolicies 1

Particulars Note No. 31st March, 2013 31st March2012

STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31ST MARCH, 2013

For and on behalf of the Board

Sd/- Sd/- M.SATYENDRA G.NAGENDRA Chairman & Managing Director Director

As per our report of even date attachedFor M. Anandam & Co.,Chartered Accountants

Sd/-S.VENKATESWARLU PartnerM.No.022790

Place : HyderabadDate : 30.05.2013

(Amount in )

Page 36: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

35

CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH, 2013

Particulars 31st March, 2013 31st March, 2012A. CASH FLOW FROM OPERATING ACTIVITIES Net Profit before Tax (18,007,403) (44,925,738)

Adjustments for : Add: Other Income (197,832) (19,252) Add:Depreciation 3,197,022 3,937,643 Add:Interest and Finance charges - 8,825,786 Add: Investments Written Off - 920,321 Decreasee/Increase in Foreign Currency Translation Reserve (3,712,923) (1,712,940) ProvisionforGratuityandLeaveencashment 300,000 (413,733) 200,000 12,151,557OperatingProfitBeforeWorkingCapitalChanges (18,421,136) (32,774,181) Changes in Working Capital (Increase)/Decrease in Trade Receivables (1,127,125) (4,349,768) (Increase)/Decrease in Other Current Assets (2,105,846) (1,738,988) Increase/(Decrease)inCurrentLiabilities 2,066,410 (1,166,561) (6,985,255) (13,074,010) Cash Flow from Operating Activities (19,587,697) (45,848,191) Taxes paid relating to earlier years (295,662) other income 197,832 - Net Cash Flow from Operating Activities (19,389,865) (46,143,853) B. CASH FLOW FROM INVESTING ACTIVITIES: Inflow/(Outflow) Net Purchase of Fixed Assets (2,129,629) (517,690) Capital Expenditure - (2,129,629) - (517,690) Net Cash Flow from Investing Activities (2,129,629) (517,690) C. CASH FLOW FROM FINANCING ACTIVITIES: Inflow / (Outflow) RepaymentofLongtermborrowings(Secured) (48,862,036) Receipt of Security Deposit 19,000,000 99,700,000 Receipt/RepaymentofLongtermborrowings(Unsecured) 754,650 19,754,650 (338,564) 50,499,400 Net Cash Flow from Financing Activities 19,754,650 50,499,400 D) NET INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS: (A+B+C) (1,764,844) 3,837,857 Cash and Cash Equivalents at the beginning of the year 4,085,621 247,764 Cash and Cash Equivalents at the close of the year 2,320,777 4,085,621 Note:Previousyear’sfigureshavebeenregroupedandrecastwherevernecessarytoconformtocurrentyear’sclassification.

(Amount in )

For and on behalf of the Board

Sd/- Sd/- M.SATYENDRA G.NAGENDRA Chairman & Managing Director Director

As per our report of even date attachedFor M. Anandam & Co.,Chartered Accountants Sd/-S.VENKATESWARLU PartnerM.No.022790Place : HyderabadDate : 30-05-2013

Page 37: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

36

Note 1:

Significant Accounting Policies:

TheaccompanyingFinancial Statements include the accountsofHeadOffice in India andoverseasbranches in USA and UK. a. Basis of preparation of financial statements

The financial statements of VJIL Consulting Limited have been prepared on a historical cost basisand is in compliance with the mandatory accounting standards issued by the Institute of Chartered Accountants of India (ICAI) as referred to in section 211(3C) of the Companies Act, 1956 (the Act). Allitemsofincomeandexpenditurehavingamaterialbearingonthefinancialstatementshavebeenrecognized on accrual basis. The accounting policies applied by the Company are consistent with those used in the previous period.

b. Use of estimates

Thepreparationoffinancialstatementsisinconformitywithgenerallyacceptedaccountingprinciples,which requires management to make estimates and assumptions that affect the reported amounts ofassetsand liabilities, thedisclosureofcontingentassetsand liabilitiesat thedateof thefinancialstatements and the reported amounts of revenues and expenses during the period reported. Examples ofsuchestimatesareusefullivesoffixedassets,percentageofcompletiononuncompletedcontracts,income taxes, post-sales customer support and provisions for doubtful debts. Actual results could differ from those estimates. The differences between actual results and estimates are recognized in the year in which the results are known / materialized.

c. Revenue recognition

Income is recognized on the signing of the agreement for sale in case of domestic sales. In the case of exports, revenue is recognized on completion of the delivery as per terms of relevant agreement or on completion basis whichever is earlier.

d. Fixed Assets

Fixed assets are stated at cost less accumulated depreciation. Cost includes all direct expenses incurred tobringanassettoworkingconditionforitsintendeduse.Costalsoincludesfinancingcostsrelatingtospecificborrowing(s)attributabletotheacquisitionorconstructionoffixedassets.

e. Depreciation

Depreciation is provided using the straight line method based on Schedule XIV of the Companies Act, 1956, which approximates the useful lives of the assets as estimated by management. Depreciation is charged on a pro-rata basis for assets purchased / sold during the period.

Page 38: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

37

f. Employee benefit plans

Contributions to Provident fund are charged to revenue. The provisions of Payment of Gratuity Act, 1972 are applicable to the Company and provision has been made in the current year on accrual basis.

g. Investments - Long term

Securitiesintendedtobeheldforaperiodexceedingoneyearareclassifiedaslongterminvestmentsand are carried at cost. Adjustments are made for any diminution in values that is, other than temporary.

h. Provisions for current and deferred tax

a. Taxation is provided for under the tax payable method, whereby all income taxes devolving upon the Company are provided for, after considering all eligible allowances and rebates. Any claims by the Revenue Authorities against the Company are evaluated as regards the likelihood of their crystallizing intoa liability.Accordingly, the claimsarequantified to theextentaccuratelydeterminableand theprovision recorded or disclosure made depending on the assessment of such likelihood. b. Deferred Tax is recognized for all the timing differences. Deferred tax assets are recognized when considered prudent. “

i. Foreign currency transactions

The expenditure and income denominated in foreign currency are converted in to rupees by applying the average yearly exchange rate. Current assets and liabilities denominated in foreign currencies are re measured as of Balance sheet at the prevailing exchange rates of the reporting currency and any differencesareaccumulatedunder“ForeignCurrencyTranslationReserve”classifiedunderReservesand Surplus. Exchange differences attributable to the acquisition of fixed assets are adjusted to the cost of theasset.

The operations of the branches at USA and UK are treated as Non integral foreign operations and hence the exchangefluctuationon restatementof foreign currency items is accumulated inForeignCurrency Translation Reserve as per AS-11.” j. Borrowing Costs

Borrowing costs that are attributable to the acquisition or construction of qualifying assets are capitalized as part of the cost of such assets. A qualifying asset is one that necessarily takes a substantial period of time to get ready for its intended use or sale.

All other borrowing costs are charged to revenue.

Page 39: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

38

k. Prior year adjustments

Significantitemsofincomeandexpenditure,whichrelatetoprioraccountingyears,areaccountedintheStatementofProfit&Lossunderthehead“Priorperiodadjustments”otherthanthoseoccasionedby events occurring during or after the close of the year and which are treated as relatable to the current year.

l. Inventories

Inventories are valued at cost

Note - 2 : Share Capital (Amount in )

Particulars 31st Mar 2013 31st Mar 2012

1) AUTHORIZED CAPITAL 90,00,000 Equity Shares of Rs.10 each 90,000,000 90,000,000 90,000,000 90,000,000 2) ISSUED CAPITAL 78,586,000 78,586,000 78,58,600 Equity Shares of Rs.10 each 78,586,000 78,586,000 SUBSCRIBED & PAID UP CAPITAL 78,58,600 Equity Shares of Rs.10 each 78,586,000 78,586,000 Total 78,586,000 78,586,000

1.1.The details of shareholders holding more than 5% shares in the company

31st March 2013 31st March 2012

Share Capital % of share Number % of share Number holding of shares holding of shares

1. Manchala Satyendra 16.93 1,330,233 16.93 1,330,233

2. M.Sunitha 5.27 414,117 5.27 414,117

Page 40: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

39

Note - 3 : Reserves & Surplus (Amount in )

Particulars 31st Mar 2013 31st Mar 2012 Capital Reserve 9,662 9,662

Total 9,662 9,662 Securities Premium 66,531,316 66,531,316

Total 66,531,316 66,531,316 Surplus/Deficit Opening balance (102,459,702) (57,102,232)Add:LosstransferredfromStatementofProfit&Loss (18,007,403) (45,357,470)

Total (120,467,105) (102,459,702)

Translation Reserve (8,580,168) (4,867,245)

Total (8,580,168) (4,867,245)

Total (62,506,295) (40,785,969)

Note - 4 : Long Term Borrowings (Amount in )

Particulars 31st Mar 2013 31st Mar 2012 Unsecured Loans From Related Parties 6,350,000 7,045,350

From Other Parties 15,279,687 13,829,687

Total 21,629,687 20,875,037 Note - 5 : Deferred Tax Liabilities (Net) Amount in Particulars 31st Mar 2013 31st Mar 2012 DeferredTaxLiability 104,650 104,650Deferred Tax liabilties (Net) 104,650 104,650

Page 41: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

40

Note - 6 : Other Long term Liabilities Amount in Particulars 31st Mar 2013 31st Mar 2012 Security Deposit 118,700,000 99,700,000 Total 118,700,000 99,700,000

Note - 7 : Long Term Provisions Amount in Particulars 31st Mar 2013 31st Mar 2012 Provision for Employee Benefits Gratuaty&LeaveEncashment 1,320,551 949,918

Total 1,320,551 949,918 Note - 8 : Other Current Liabilities Amount in Particulars 31st Mar 2013 31st Mar 2012

Others Creditors for Expenses 22,353,060 19,818,061 Statutory Dues 22,537,453 22,430,663 Duties & Taxes Payable 2,896,896 2,946,896 Interest on Borrowings 11,146,863 11,146,863 Rent Payable 5,494,202 7,405,652 Salaries Payable 4,788,539 3,402,468 Total 69,217,013 67,150,603

Note - 9 : Short Term Provisions Amount in

Particulars 31st Mar 2013 31st Mar 2012

Provision For Employee Benefits: Gratuity&Leaveencashment 3,069,024 3,139,657 Total 3,069,024 3,139,657

Page 42: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

41

Not

e - 10

: Fix

ed A

sset

s - T

angi

ble A

sset

s

A

mou

nt in

GR

OSSBLO

CK

D

EPRE

CIAT

IONNET

BLO

CKAS

SET

As at

Ad

ditio

ns

Delet

ions

As at

Up

to

For t

he

on

As at

As

on

As on

01

.04.20

12

31.03

.2013

01

.04.20

12

year

De

letion

s

31.03

.2013

31

.03.20

13

31.03

.2012

Land

25,36

5,802

-

-

25,36

5,802

-

-

-

-

25,36

5,802

25,36

5,802

Furn

iture

& Fix

tures

27

,446,7

74

681,3

47

28

,128,1

21

21,38

7,673

1,

739,8

00

-

23,12

7,473

6,

059,1

01

5,00

0,648

Elec

trica

l Insta

llatio

ns

9,44

2,548

43

1,124

-

9,

873,6

72

9,44

2,548

6,

036

-

9,44

8,584

-

42

5,088

OfficeE

quipme

nt

2,637,3

82

382,0

69

-

3,019,4

51

834,4

62

170,9

32

-

1,005,3

94

1,802,9

20

2,014,0

57

Comp

uter

& Ac

cesso

ries

93,20

5,002

63

5,089

-

93

,840,0

91

86,66

9,746

1,

148,1

26

-

87,81

7,872

6,

535,2

56

6,02

2,219

Airco

nditi

oning

2,

533,1

85

-

-

2,53

3,185

1,

924,4

33

120,3

26

-

2,04

4,759

60

8,752

48

8,426

Fire E

quip

ment

24

8,461

24

8,461

19

3,790

11

,802

-

205,5

92

54,67

1 42

,869

Library

198,0

34

-

-

198,0

34

108,7

27

-

-

108,7

27

89,30

789

,307

Vehic

les

7,01

5,697

-

-

7,

015,6

97

7,01

5,697

-

-

7,

015,6

97

-

-

Total

16

8,092

,885

2,12

9,629

-

17

0,222

,514

127,5

77,07

6 3,

197,0

22

-

130,7

74,09

8 40

,515,8

09

39,44

8,416

Prev

ious

Year

16

7,575

,195

517,6

90

-

168,0

92,88

5 12

3,639

,433

3,93

7,643

-

12

7,577

,076

40,51

5,809

43

,935,7

62

Page 43: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

42

Note - 11 : Non Current Investments Amount in

Particulars 31st Mar 2013 31st Mar 2012 Investments in Subsidiary Companies 29210600 29210600Mercury Outsourcing Management - Fully Owned Subsidiary Company (2921060 equity shares of Rs.10 each Fully paid)

Total 29210600 29210600 Note - 12 : Long Term Loans and Advances Amount in Particulars 31st Mar 2013 31st Mar 2012

Unsecured, Considered Good : Deposits with Governement Departments 215800 166700Employee Advances 2986988 3638357Other Deposits 4995758 2980835Other Advances 27870491 26875382AdvancestoSubsidiary(MOMLtd) 27609893 27911810Tax Deducted at source & service tax receivable 600803 600803

Total 64279732 62173887 Note - 13 : Other Non Current Assets Amount in

Particulars 31st Mar 2013 31st Mar 2012

LongTermTradeReceivables Unsecured Considered Good 22129163 22,647,860Unsecured Considered Doubtful 68295419 65,110,272 Sub total 90424582 87,758,132

Less:AllowanceforBadanddoubtfuldebtors 68295419 65,110,272 Total 22129163 22647860 Note - 14 : Inventory Amount in

Particulars 31st Mar 2013 31st Mar 2012

Computer Software 58481134 58481134Course Material 107118 107118

Total 58588252 58588252

Page 44: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

43

Note - 15 :Trade Receivables Amount in

Particulars 31st Mar 2013 31st Mar 2012

Outstanding for less than six months a) Unsecured, Considered Good : 8,590,727 6,944,905

Total 8,590,727 6,944,905 Note - 16 : Cash & Cash Equivalents Amount in

Particulars 31st Mar 2013 31st Mar 2012 Balances with banks in current Accounts 917007 4085295 Cash on hand 103770 326 Cash - Inprest 13,00,000 -

Total 2320777 4085621

Note - 17 : Revenue from Operations Amount in Particulars 31st Mar 2013 31st Mar 2012 Consulting Income 31,002,715 14,345,519

Total 31,002,715 14,345,519 Note - 18 : Other Income Amount in Particulars 31st Mar 2013 31st Mar 2012

Other Income 131,210 10,030 Exchangefluctuation 66,622 9,222

Total 197,832 19,252 Note - 19 : Employee benefits expenses Amount in Particulars 31st Mar 2013 31st Mar 2012

Salaries 19,873,423 16,802,148 Contribution to Provident Fund & Other funds 1,187,178 797,235 Employees welfare expenses 65,510 60,846 Total 21,126,111 17,660,229

Page 45: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

44

Note - 20 : Finance Costs Amount in Particulars 31st Mar 2013 31st Mar 2012 Interest on Cash Credit - 8,825,786

Total - 8,825,786

During the year the company has not provided interest on unsecured loans received from various partiesdue to the requestmadeby the company for reduction/waiver of interestdue to financialposition of the company. Note - 21 : Other Expenses Amount in Particulars 31st Mar 2013 31st Mar 2012

Administrative Expenses Fuel & Electricity Charges 1,553,185 1,524,424 Directors Remuneration 2,400,000 2,400,000 Insurance 318,083 113,726 Rent 1,169,468 5,838,189 Rates & Taxes 125,745 102,554 Foreign Tour & Traveling Expenses 975,608 1,520,160 Bank Charges 270,882 271,922 Conveyance 59,661 87,006 Printing & Stationery 28,273 24,429 Repairs & Maintenance 713,255 816,499 Communication Expenses 585,170 625,298 OfficeMaintenance 811,031 692,880Auditors Remuneration - Statutory Audit Fees 75,000 75,000 - Tax Audit Fees 25,000 25,000 - Other Matters 50,000 50,000 Legal&ProfessionalCharges 3,195,411 5,324,487AGM Expenses 254,400 274,112 Advertisement 43,663 23,463 Consulting Charges 8,188,531 4,360,345 watch and ward expenses 264,064 247,776 Penalties 123,086 87,166 Investments Written Off - 920,321 Subcriptions 370,758 185,304 Training Expenses 56,300 246,454 Interest on PF Contribution 949,454 -

Page 46: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

45

Recruiment charges 264,275 257,543 Refreshment Expenses 91,989 84,043 Interest on TDS - 968,417 AMC charges 6,112 7,300 Misc expenses 164,300 298,669 Business Promotion 975,143 899,025 Marketing Exp 567,975 414,930 LicencesandRenewals 203,134 96,790Books and periodicals 5,860 3,620 Total (A) + (B) + (c) 24,884,817 28,866,852 Note - 22 : Payments to Auditors Amount in 31st Mar 2013 31st Mar 2012 Statutory Audit Fees 75,000 75,000 Tax Audit Fees 25,000 25,000 Other Matters 50,000 50,000 Out of Pocket Expenses 1,000 650 Total 151,000 150,650 Note - 23 : Directors Remuneration Amount in Particulars 31st Mar 2013 31st Mar 2012 Chairman and Managing Director 2,400,000 2,400,000 Total 2,400,000 2,400,000 Note - 24 : Expenditure in Foreign Currency Amount in

Particulars 31st Mar 2013 31st Mar 2012 Expenditure 16,051,109 12,076,880 Total 16,051,109 12,076,880 Note - 25 : Earnings in Foreign Currency Amount in Particulars 31st Mar 2013 31st Mar 2012 Earnings 31,002,715 14,345,519 Total 31,002,715 14,345,519

Page 47: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

46

Note -26 : Earning Per Share (EPS) Amount in Particulars 31st Mar 2013 31st Mar 2012 ProfitfortheYearaftertax (18,007,403) (44,925,738)Number of Equity Shares 7858600 7858600Earnings Per Share (Basic and Diluted) (2.29) (5.72)Face Value of each Equity Share (Rs.) 10 10

Note - 27 : Related Party Disclosure : The Company has transactions with the following related parties: a)WhollyownedSubsidiary:MercuryOutsourcingManagementLtd

b) Key Management Personnel: Chairman & Managing Director:- M.Satyendra c) Associate Entity in which Directors have Substantial Interest: YemmenAgroPrivateLimited,TholonsKnowledgeManagementPvtLtd d) Relatives of Key Management Personnel : M.Sunitha, Ravinder, Shankara Kumari, RVSC Bose B) The following transactions are carried out with related parties in the course of business

Particulars Subsidiary Key managerial Associate Relatives of Companies Persons Entities in Key managerial which Directors Persons have Substantial Interest

Rendering of Services - 2,400,000 - - LoansGiven 27,609,893 - - -LoansReceived - - 2,750,000 3,600,000Investment 29,210,600 - - -

Total 56,820,493 2,400,000 2,750,000 3,600,000

Amount in

Page 48: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

47

Note - 28 : Contingenet Liabilities not provided for Claims against the Company not acknowledged as debt: Particulars Amount in DisputedLiabilityinrespectofIncomeTaxdemandsrelatedtoF.Y.2004-05 pending at High Court of A.P. 6,041,474

DisputedLiabilityinrespectofTDSdemandsrelatedtoF.Y.2007-08 pending at CIT (Appeals) 28,225,409

DisputedLiabilityinrespectofTDSdemandsrelatedtoF.Y.2008-09 pending at CIT (Appeals) 21,798,425

Note 29.

Detailed break up of party wise/item wise balances with regard to opening balances in respect of majority of the assets and liabilities are not available with the Company. On the basis review made by the management necessary provision has already been made in the books of accounts Note 30.

DuringtheyeartheCompanyhasphysicallyverifiedthecomputersandOfficeEquipments.TheFixedassets register of the Company for earlier years is not traceable and the Management is in the process of updationoftheFixedAssetsregister.ThevalueoffixedassetsissubjecttoreviewbytheManagementand reconciliation. The consequential impact on the accounts is not ascertainable as at present. Note 31.

CertainlongtermtradereceivablesofRs.176.29Lakhs,DepositsofRs.19.00Lakhs,loansandadvancesofRs.234.46lakhs,longtermborrowingsofRs.216.29LakhsandothercurrentliabilitiesofRs.62.46lakhsaresubjecttoconfirmationandreconciliation.

Page 49: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

48

Note 32.

Thecompanyhasan investmentofRs.292.10Lakhs in the share capital, loansandadvancesofRs.276.09LakhsandlongtermtradereceivablesofRs.45.00lakhsinMercuryOutsourcingManagementLtd,subsidiarycompany.Inviewofthelongterminvolvementofthecompanyinthesaidcompanyno provision has been made in the accounts for the probable loss that may arise on the same. Note 33.

There is a pendig legal dispute against the immovable properties located at Manikonda villiage and Kondapur Village, Ranga Reddy District. However the Company is of the hope in resolving the matter positively. Note 34: Dues to Micro Small and Medium Enterprises:

There are no dues to the Small scale Industrial Undertaking exceeding Rupees one lakh which is outstanding for more than 30 days as per the information available with the Company as on date. Note 35

The company has made relevant disclosures which are applicable as per revised schedule VI and the figuresfortheprevious year are reclassified/regroupedandrearrangedwherevernecessary.

Page 50: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

49

Information about the Geographical Segments Amount in ’000 For the year ended 31st March, 2013 For the year ended 31st March, 2012 India Outside Consolidated India Outside Consolidated India India

Revenue External Sales 6584.20 24,418.52 31,002.71 688.51 13,657.00 14,345.51 Inter Segment Sales - - - - - - Total Revenue 6584.20 24,418.52 31,002.71 688.51 13,657.00 14,345.51 Segment Result (23223.18) 8367.41 (14855.78) (36,138.30) 2,419.08 (33,719.22)Unallocated corporate expenses 3,349.45 2,400.00 OperatingProfit (18,205.23) (36,119.22)Interest expense - 8,825.79 Other income 197.83 19.25 Income taxes 0 - Profitfromordinaryactivities (18,007.40) (44,925.75)Extra ordinary loss Net profit (18,007.40) (44,925.75)Other information Segment assets 133,519.91 (7,380.48) 126,139.43 Unallocated corporate assets 133,519.91

Total assets SegmentLiabilities 20,875.04 - 20,875.04UnallocatedCorporateLiabilities TotalLiabilities 20,875.04Capital expenditure Depreciation 3,183.38 13.64 3197.02 3,920.71 16.94 3,937.65 Non cash expenses other than Depreciation

For and on behalf of the Board

Sd/- Sd/- M.SATYENDRA G.NAGENDRA Chairman & Managing Director Director

As per our report of even date attachedFor M. Anandam & Co.,Chartered Accountants

Sd/-S.VENKATESWARLU PartnerM.No.022790

Place : HyderabadDate : 30-05-2013

Note 36:The company is in the business of Software Consulting and Development. The Company’s primary reporting segment is geographical as revenue segment.

Page 51: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

50

VJIL CONSULTING LIMITEDRegisteredOffice:3rd Floor Western Wing, NCC House, Survey No-64, Madhapur,

Hyderabad-500081.ATTENDANCE SLIP

(To be handed over at the entrance of the meeting hall)21ST ANNUAL GENERAL MEETING THURSDAY 19TH SEPTEMBER, 2013

I/We hereby record/my/our presence at the 21st Annual General Meeting of the Members of the Company will be held at Tyagaraya Gana Sabha, Chikkadpalli, Hyderabad - 500095 on Thursday 19th September, 2013 at 10.00 A.M.

Full Name of the Member :..............................................................................................................................(InBlockLetters)

Regd. Folio No. :........................................................ No of Shares held.......................................................Full Name of Proxy :

Full Name of Proxy :.........................................................................................................................................(InblockLettrs)

SIGNATURE(S) OF THE MEMBER(S) OR PROXY / PROXIES PRESENT

PROXY FORM

Regd. Folio No. :............................................................... No of Shares held...............................................I/We................................................................................................. of................................................................ being a Member/Members of VJIL CONSULTING LIMITED here by appoint.............................................................................................................................of.....................................................................................failing him/her.......................................................................of...............................................................................................of....................................................................as my/our proxy to attend and vote for me/us and on my /our behalf on at Tyagaraya Gana Sabha, Chikkadpalli, Hyderabad - 500095 on Thursday 19th September, 2013 at 10.00 A.M.

As Witnessed my hand / our hands this.................day of............................2013

Signature................................................

Note : The form order to be effective should be duly completed, stamped and signed and must be deposited at theRegisteredOfficeoftheCompany48hoursbeforethemeeting.

Signatureaccross

Re. 1Revenue

Stamp

Page 52: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and

If undelivered please return to:VJIL CONSULTING LIMITEDRegisteredOffice:3rd Floor Western Wing, NCC House, Survey No-64, Madhapur, Hyderabad-500081.

BOOK - POST

Page 53: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and
Page 54: 21ST ANNUAL REPORT 2012 - 13 · 2014-03-27 · Amrutha Ville Apt., Opp.Yashodha Hospital, Raj Bhavan Road,Somajiguda, Hyderabad-500082 LISTED AT: ... for Thio Pharmaceuticals and